Stock Market & Financial Investment News

News Breaks September 28, 2012 05:52 EDT DNDN Dendreon: 1st patient in EU open-label study begins Sipuleucel-T treatment Dendreon announced the first patient enrollment and initiation of treatment for the sipuleucel-T European Union, or EU, open-label study. The open-label study is being conducted in European men with metastatic castrate-resistant prostate cancer, or mCRPC, to describe product release parameters and report on safety in a European population. The study may enroll up to 45 patients in four sites across the EU. Dendreon has submitted a marketing authorization application, or MAA, for sipuleucel-T which is currently under review by the European Medicines Agency, or EMA. Sipuleucel-T is not approved for use outside the U.S. Sipuleucel-T is approved by the FDA in the U.S. for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. It is marketed under the name PROVENGE. News For DNDN From The Last 14 Days Check below for free stories on DNDN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 10, 2013 10:00 EDT DNDN On The Fly: Analyst Downgrade Summary Subscribe for More Information 09:38 EDT DNDN Active equity option families trading Subscribe for More Information 09:21 EDT DNDN On The Fly: Pre-market Movers Subscribe for More Information 07:55 EDT DNDN Dendreon may generate near-term trading opportunity, says RW Baird Subscribe for More Information 07:44 EDT DNDN Dendreon price target lowered to $1 from $5 at BofA/Merrill Subscribe for More Information 07:40 EDT DNDN Dendreon price target lowered to $6.50 from $9 at Bernstein Subscribe for More Information 05:51 EDT DNDN Dendreon downgraded to Sell from Neutral at Citigroup Subscribe for More Information May 9, 2013 14:15 EDT DNDN Dendreon downgraded to Sell from Neutral at Roth Capital Subscribe for More Information 13:32 EDT DNDN Dendreon downgraded to Sell from Hold at Stifel Subscribe for More Information 12:35 EDT DNDN On The Fly: Midday Wrap Subscribe for More Information 10:56 EDT DNDN Dendreon price target lowered to $3 from $4 at Maxim Subscribe for More Information 08:42 EDT DNDN Dendreon reports Q1 EPS (48c), consensus (48c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.